Product Information - Amvalan 10 mg /160 mg
- Dual Mechanism, Superior Control
Combines a CCB and ARB for complementary, potent blood pressure reduction
- Guideline- Recommended First-Line Choice
Endorsed by ESC/ESH & ACC/AHA as a preferred single-pill combination for hypertension.
- Consistent Results Across High-Risk Populations
Proven efficacy in elderly, diabetic, and cardiovascular-risk patients.
- Better Tolerability, Fewer Side Effects
Reduced risk of edema (vs. high-dose amlodipine) and cough (vs. ACE inhibitors).
- Rapid & Sustained Efficacy
Achieves target BP in 70–80% of patients within 4–8 weeks — effective in both mild and severe hypertension.
- Dose-Responsive BP Reduction
Delivers incremental blood pressure lowering with each dose increase.
- Improved Adherence Through SPC
Once-daily dosing improves compliance and treatment persistence.
